Inotiv and Envigo Join Forces to Enhance Research and Drug Discovery Solutions

Combined, Inotiv and Envigo create value for our clients through our uniquely differentiated, scaled, and broad product and service offering, featuring:

**Full-Spectrum Services:**
- Integrated leader in contract pharmaceutical research
- Suite of nonclinical and analytical services integrated with the widest and most innovative range of research models
- Unique ability to leverage expansive research model portfolio to enable delivery of broader service offerings
- Expanded access to scientists and enhanced facility footprint in North America and Western Europe
- Ability to reduce nonclinical lead times and enhance project delivery

**Complementary Businesses:**
- Help meet expanding needs required to bring new drugs and medical devices through the discovery and preclinical phases of development
- Complementary client base (Inotiv biopharma, Envigo adds CRO and academic)
- Ability to run selected nonclinical studies directly on-site at research model facilities
### Capabilities and Values of Inotiv and Envigo

**A Leading One-Stop-Shop Provider of Preclinical CRO Services**

<table>
<thead>
<tr>
<th>Drug Discovery</th>
<th>Preclinical Development</th>
<th>Clinical Development</th>
</tr>
</thead>
<tbody>
<tr>
<td>Full suite of discovery services providing right-sized solutions for in vivo discovery, bioanalysis and toxicology</td>
<td>Comprehensive GLP services supporting preclinical development</td>
<td>Analytical services supporting molecules through development</td>
</tr>
<tr>
<td>Best-in-class research models and services platform with bespoke offerings</td>
<td>Long-standing customer relationships across therapeutic areas</td>
<td></td>
</tr>
</tbody>
</table>

**Clients Will Benefit From:**

1. **INTEGRATED SOLUTIONS**
   - A comprehensive suite of nonclinical and analytical/bioanalytical services integrated with the widest and most innovative range of research models
   - Allow drug developers to work with one organization to support the development of their molecules for the entirety of discovery and nonclinical development

2. **DEEP AND PROVEN EXPERTISE AND SCIENTIFIC CAPABILITIES**
   - Inotiv’s scientific leadership, long and impeccable regulatory history, and world-class team of scientists who deliver a comprehensive range of nonclinical and analytical/bioanalytical services
   - Envigo’s long history and deep experience with supply of critical research models
     - Leading global provider of large research models, including non-human primates (NHPs)
     - Wide range of high-quality, small research models for basic research and drug discovery, as well as specialized disease and therapeutic area specific models
     - Genetically engineered models and services (GEMS), contract breeding services, Teklad laboratory animal diets, surgical services, animal health monitoring, and custom antibody manufacturing services

**The Combined Companies Have:**

- **~3,000 CUSTOMERS AROUND THE GLOBE**
- **~1,800 EMPLOYEES**
- **25 LOCATIONS ACROSS TWO CONTINENTS AND SIX COUNTRIES**

---

**Bob Leasure**  
Inotiv CEO

“Supported by deep, in-house expertise and scientific capabilities, we’re building a comprehensive contract pharmaceutical research solutions provider with a full spectrum of discovery and nonclinical services and research models into a unique, one-stop-shop, discovery-to-approval solution for drug developers.”

**Dr. Adrian Hardy**  
Envigo CEO

“Our diverse client base of CROs, pharmaceutical, government and academic institutions and Inotiv’s biopharma clients will be able to utilize leading research models and services from Envigo, including genetically engineered models and services (GEMS), contract breeding services, Teklad laboratory animal diets, surgical services, custom antibody services, and large and small research models.”